Does cardiac exposure to radiation and anthracyclines increase the risk of heart failure in survivors of Hodgkin lymphoma?
Higher doses of cardiac radiation and the use of anthracyclines synergistically increase the long-term risk of heart failure in Hodgkin lymphoma survivors.
= .09). Twenty-five-year cumulative risks of HF following MLVDs of 0-15 Gy, 16-20 Gy, and ≥21 Gy were 4.4%, 6.2%, and 13.3%, respectively, in patients treated without anthracycline-containing chemotherapy, and 11.2%, 15.9%, and 32.9%, respectively, in patients treated with anthracyclines. We have derived quantitative estimates of HF risk in patients treated for HL following radiotherapy with or without anthracycline-containing chemotherapy. Our results enable estimation of HF risk for patients before treatment, during radiotherapy planning, and during follow-up.
Nimwegen et al. (Wed,) studied this question.